VCI Wealth Management LLC Invests $879,000 in Edwards Lifesciences Co. (NYSE:EW)

VCI Wealth Management LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,534 shares of the medical research company’s stock, valued at approximately $879,000.

Several other hedge funds also recently made changes to their positions in the business. Turtle Creek Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at $34,000. Operose Advisors LLC grew its stake in shares of Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after buying an additional 452 shares in the last quarter. SRS Capital Advisors Inc. grew its stake in shares of Edwards Lifesciences by 292.6% in the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after buying an additional 474 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Edwards Lifesciences in the third quarter valued at $52,000. Finally, ORG Partners LLC bought a new position in shares of Edwards Lifesciences in the third quarter valued at $66,000. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on EW. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Wells Fargo & Company raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective for the company in a research report on Friday, February 2nd. Evercore ISI lifted their price objective on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research report on Wednesday, February 7th. Finally, StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $91.73.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 over the last three months. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded down $0.60 during midday trading on Thursday, reaching $88.01. The company’s stock had a trading volume of 4,166,251 shares, compared to its average volume of 3,829,875. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The business’s 50 day moving average price is $90.23 and its two-hundred day moving average price is $78.69. The company has a market cap of $52.98 billion, a P/E ratio of 38.53, a P/E/G ratio of 4.35 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.64 earnings per share. On average, analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.